Last €2.84 EUR
Change Today +0.07 / 2.53%
Volume 944.7K
ZEL On Other Exchanges
Symbol
Exchange
Continuous
OTC US
OTC US
As of 11:38 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZEL) Snapshot

Open
€2.78
Previous Close
€2.77
Day High
€2.87
Day Low
€2.78
52 Week High
06/19/14 - €3.13
52 Week Low
11/21/13 - €2.25
Market Cap
631.1M
Average Volume 10 Days
225.7K
EPS TTM
€0.06
Shares Outstanding
222.2M
EX-Date
07/15/11
P/E TM
44.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for ZELTIA SA (ZEL)

Related News

No related news articles were found.

zeltia sa (ZEL) Related Businessweek News

No Related Businessweek News Found

zeltia sa (ZEL) Details

Zeltia, S.A. operates in the biopharmaceutical industry and consumer chemical sectors. It researches, develops, produces, and markets various types of bioactive products of marine origin for application in oncology; and products with therapeutic activity based on reducing or silencing gene expression and pharmaceutical derivatives of same in a range of formulations, as well as develops and markets biopharmaceutical applications, diagnosis, and related services. The company’s products include Yondeli, a marketed product for the treatment of ovarian cancer and soft tissue sarcoma; Aplidi, which is in Phase III trials for the treatment of multiple myeloma, as well as in angioimmunoblastic Tcell lymphoma; Zalypsi that is in Phase II trials for the treatment of multiple myeloma; PM1183, which has completed Phase IIb trials for the treatment of platinum-refractory/resistant ovarian cancer; PM060184 that is in Phase I trials for the treatment of various types of tumors; and SYL040012, which is in Phase IIB clinical trials for the treatment of glaucoma. It also develops and markets diagnosis kits. In addition, the company is involved in the manufacture and sale of wood and metal protective and decorative products, paints, and other related products; manufacture and marketing of domestic and industrial insecticides and air fresheners for household use; manufacture and sale of automatic aerosol dispensers under the Copyrmatic brand; and production of products for ecological farming. Further, it provides services for treating and protecting wood, and repairing and preserving structures, as well as insect control and disinfection services. Zeltia, S.A. was founded in 1939 and is headquartered in Madrid, Spain.

Founded in 1939

zeltia sa (ZEL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeltia sa (ZEL) Key Developments

Zeltia Announces Earnings Results for the Second Quarter and First Half Ended June 30, 2014

Zeltia announced earnings results for the second quarter and first half ended June 30, 2014. For the quarter, the company reported that loss attributable to equity-holders of the parent was €147,000, compared to a loss attributable to equity-holders of the parent of €1.41 million for the same quarter ended June 30, 2013. Total revenue was €44.92 million, compared to €41.03 million for the same quarter ended June 30, 2013. For the first half, the company reported net sales amounted to €78.2 million up 10% with respect to the same period last year. EBITDA amounted to €22.1 million in first half of 2014, a 12% increase with respect to the same period last year. The oncology area was the main contributor to this performance, accounting for €24 million against €22.5 million in first half of 2013. EBITDA increased notably despite the increase in R&D spending +9.8%, attributable mainly to the pivotal Phase III trial with Aplidin in multiple myeloma. Income attributable to equity-holders of the parent was €16.75 million, compared to €14.40 million for the same period ended June 30, 2013. Total revenue was €98.05 million, compared to €91.19 million for the same period ended June 30, 2013.

Zeltia SA to Report Q2, 2014 Results on Jul 29, 2014

Zeltia SA announced that they will report Q2, 2014 results on Jul 29, 2014

Zeltia S.A. Reports Earnings Results for the First Quarter Ended March 31, 2014

Zeltia S.A. reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported a profit attributable to owners of the parent of EUR 16.90 million compared to EUR 15.82 million for the same quarter ended March 31, 2013. Net revenues were EUR 34.21 million, compared to EUR 30.81 million for the same quarter ended March 31, 2013. Net operating profit was EUR 18.08 million compared to EUR 16.46 million for the same quarter ended March 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEL:SM €2.84 EUR +0.07

ZEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEL.
View Industry Companies
 

Industry Analysis

ZEL

Industry Average

Valuation ZEL Industry Range
Price/Earnings 41.4x
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 41.0x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit www.zeltia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.